Welcome to our dedicated page for ROCKET PHARMACEUTICALS SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKET PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKET PHARMACEUTICALS's regulatory disclosures and financial reporting.
Rocket Pharmaceuticals, Inc. (RCKT) adopted a new Severance and Change in Control Program covering U.S. employees not already under separate severance arrangements. Eligibility for non-change-in-control severance requires at least one year of service, and benefits are conditioned on signing a release of claims. The program replaces prior severance arrangements but allows individually approved exceptions.
Rocket also entered into updated executive employment arrangements. CEO Gaurav Shah’s agreement provides a base salary of $674,856, a target bonus of 60% of base salary, and cash and COBRA severance enhancements if terminated without Cause or for Good Reason, with larger amounts upon a qualifying Change in Control termination. General Counsel and Chief Corporate Officer Martin Wilson’s agreement provides a base salary of $547,313, a 45% target bonus, and similar severance and COBRA protections, including enhanced change-in-control terms. An amendment for COO Christopher Stevens aligns his severance and change-in-control protections with this framework while leaving the rest of his prior agreement in effect.
ROCKET PHARMACEUTICALS, INC. (RCKT) reported that General Counsel Martin Wilson sold 631 shares of common stock on 2026-08-18 at $3.381 per share. According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units. After this transaction, Wilson directly holds 673,853 shares, including RSUs that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. (RCKT) CEO Gaurav Shah reported selling 2,293 shares of common stock on 2026-08-18 at $3.381 per share. The sale was made to pay tax withholding obligations related to vesting Restricted Stock Units (RSUs). After this transaction, he holds 1,056,594 shares directly (including RSUs), plus 207,897 shares held indirectly by his spouse and 198,341 shares held indirectly by the Gaurav D. Shah Irrevocable Trust.
ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer for which Gaurav Shah has filed a Rule 144 notice to sell restricted common stock. The notice covers a proposed sale of 2,293 shares, arising from restricted stock vesting on August 14, 2026, with prior sales disclosed over the preceding three months.
ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer for a planned resale of common stock under Rule 144 for the account of officer Martin Wilson. A notice was filed for the potential sale of 631 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $2,133.66 as of 08/18/2026 on NASDAQ. The shares derive from restricted stock vesting on 08/14/2026 and are characterized as compensation. In the prior three months, Wilson reported sales of 662 shares for $1,995.53 on 05/19/2026 and 3,493 shares for $11,810.18 on 08/13/2026. The filer notes that the sale includes shares to cover a tax obligation from the settlement of a vested equity award.
ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer for which a Form 144 notice has been filed relating to planned sales of common stock held for the account of former officer John Militello. The notice lists 1,252 shares of common stock held in an account at Fidelity Brokerage Services LLC as of 08/18/2026, with a stated market value of $4,233.51 and listing on NASDAQ.
The filing discloses that Militello received restricted stock vesting events of 887 shares on 08/11/2026 and 365 shares on 08/14/2026 as compensation from the issuer, and that 384 shares of common stock were sold on 05/19/2026 for $1,157.53 during the prior three months. A remark explains that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a sale of 2,837 shares of common stock on 2026-08-13 at $3.3810 per share. According to the company’s disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). After this sale, Shah held 1,058,887 shares directly, which include RSUs that convert to common stock on a one-for-one basis, plus indirect holdings of 207,897 shares through his spouse and 198,341 shares through the Gaurav D. Shah Irrevocable Trust.
ROCKET PHARMACEUTICALS, INC. executive Martin Wilson, General Counsel, reported a sale of 3,493 shares of common stock on 2026-08-13 at $3.381 per share. The sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units, and Wilson now holds 674,484 shares directly, including RSUs that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. Chief Operating Officer Christopher James Stevens reported selling 36,658 shares of common stock on 2026-08-11 at $3.499 per share. According to the company’s disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). Following this tax-related sale, Stevens directly holds 505,784 shares of common stock, including RSUs that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. executive Sarbani Chaudhuri sold 4,701 shares of common stock on August 11, 2026, at $3.499 per share. The filing states the shares were sold to pay tax withholding obligations related to vesting RSUs. After this transaction, Chaudhuri directly held 262,809 shares, including Restricted Stock Units that convert to common stock on a one-for-one basis.